- 期刊
Preferential Selectivity of Inhibitors with Human Tau Protein Kinase Gsk3β Elucidates Their Potential Roles for Off-Target Alzheimer's Therapy
延伸閱讀
- 蔣妮霓（2020）。Promoting BDNF-TRKB signaling as a therapeutic strategy for Alzheimer’s disease treatment using ΔK280 TauRD-DsRed SH-SY5Y cell model〔碩士論文，國立臺灣師範大學〕。華藝線上圖書館。https://doi.org/10.6345/NTNU202001383
- Koistinaho, J., Malm, T., & Goldsteins, G. (2011). Glycogen Synthase Kinase-3β: A Mediator of Inflammation in Alzheimer's Disease?. International Journal of Alzheimer＇s Disease, 2011(), 40-48. https://doi.org/10.4061/2011/129753
- 李佳瑜（2021）。Identification of therapeutic compounds possessing potential activity of TrkB agonists using Alzheimer's mouse primary culture and animal models〔碩士論文，國立臺灣師範大學〕。華藝線上圖書館。https://doi.org/10.6345/NTNU202101587
- Tyagi, E., Fiorelli, T., Norden, M., & Padmanabhan, J. (2013). Alpha 1-Antichymotrypsin, an Inflammatory Protein Overexpressed in the Brains of Patients with Alzheimer's Disease, Induces Tau Hyperphosphorylation through c-Jun N-Terminal Kinase Activation. International Journal of Alzheimer＇s Disease, 2013(), 119-129. https://doi.org/10.1155/2013/606083
- Martinez, A., Gil, C., & Perez, D. I. (2011). Glycogen Synthase Kinase 3 Inhibitors in the Next Horizon for Alzheimer's Disease Treatment. International Journal of Alzheimer＇s Disease, 2011(), 257-263. https://doi.org/10.4061/2011/280502